{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:46:36Z","timestamp":1789739196141,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.annonc.2022.04.068","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T21:58:03Z","timestamp":1651183083000},"page":"794-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein\u2013Barr virus DNA in post-treatment plasma"],"prefix":"10.1016","volume":"33","author":[{"given":"D.C.T.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K.J.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.B.Y.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.C.T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.M.D.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2022.04.068_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2022.04.068_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jnci\/dji084","article-title":"Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma","volume":"97","author":"Chan","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2022.04.068_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib5","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-20-3519","article-title":"Dynamic changes of post-radiotherapy plasma Epstein-Barr virus DNA in a randomized trial of adjuvant chemotherapy versus observation in nasopharyngeal cancer","volume":"27","author":"Hui","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.04.068_bib6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib7","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","article-title":"Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety","volume":"23","author":"Wee","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib8","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.28049","volume":"119","author":"Chen","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2022.04.068_bib9","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1002\/cncr.30850","volume":"123","author":"Lee","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2022.04.068_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JOP.18.00219","article-title":"Management of nasopharyngeal carcinoma: is adjuvant therapy needed?","volume":"14","author":"Lee","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.annonc.2022.04.068_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CCO.0000000000000622","article-title":"The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma","volume":"32","author":"Hui","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/EDBK_280747","article-title":"Recent advances in the development of biomarkers and chemoradiotherapeutic approaches for nasopharyngeal carcinoma","volume":"40","author":"Ma","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.annonc.2022.04.068_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","article-title":"Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial","volume":"75","author":"Chen","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2022.04.068_bib15","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2018.77.7847","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","volume":"36","author":"Chan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib16","first-page":"1188","article-title":"Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2022.04.068_bib17","first-page":"5452","article-title":"Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2022.04.068_bib18","first-page":"6878","article-title":"Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA","volume":"60","author":"Lo","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2022.04.068_bib19","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2022.04.068_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1373\/clinchem.2003.022426","article-title":"Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody","volume":"50","author":"Leung","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.annonc.2022.04.068_bib21","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.04.068_bib22","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","article-title":"Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma","volume":"24","author":"Leung","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib23","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28001","article-title":"Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program: early NPC detection in plasma EBV DNA","volume":"119","author":"Chan","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2022.04.068_bib24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","article-title":"Plasma Epstein\u2013Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma","volume":"25","author":"Leung","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein\u2013Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.04.068_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clon.2010.09.001","article-title":"Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy","volume":"23","author":"Hou","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.annonc.2022.04.068_bib27","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3892\/ol.2015.3628","article-title":"Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma","volume":"10","author":"Zhao","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.annonc.2022.04.068_bib28","doi-asserted-by":"crossref","first-page":"E5115","DOI":"10.1073\/pnas.1804184115","article-title":"Sequencing-based counting and size profiling of plasma Epstein\u2013Barr virus DNA enhance population screening of nasopharyngeal carcinoma","volume":"115","author":"Lam","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2022.04.068_bib29","first-page":"3431","article-title":"Disparity of sensitivities in detection of radiation-na\u00efve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA","volume":"9","author":"Leung","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.04.068_bib30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/path.5249","article-title":"Plasma Epstein\u2013Barr virus DNA as an archetypal circulating tumour DNA marker","volume":"247","author":"Lam","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.annonc.2022.04.068_bib31","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","article-title":"An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma","volume":"19","author":"Le","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.04.068_bib32","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","article-title":"Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma","volume":"10","author":"Lv","year":"2019","journal-title":"Nat Commun"},{"issue":"302","key":"10.1016\/j.annonc.2022.04.068_bib33","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annonc.2022.04.068_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","article-title":"Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery","volume":"65","author":"Reinert","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.annonc.2022.04.068_bib35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.15252\/emmm.201404913","article-title":"Serial monitoring of circulating tumor in patients with primary breast cancer for detection of occult metastatic disease","volume":"7","author":"Olsson","year":"2015","journal-title":"EMBO Mol Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422007530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422007530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:09:47Z","timestamp":1760335787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753422007530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0923753422007530"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.04.068","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein\u2013Barr virus DNA in post-treatment plasma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.04.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}